Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
09 2019
Historique:
received: 26 10 2018
revised: 02 05 2019
accepted: 03 05 2019
pubmed: 31 5 2019
medline: 7 5 2020
entrez: 31 5 2019
Statut: ppublish

Résumé

Preclinical models are much needed to assess the effect of novel radio-sensitizers or mitigators on radiation dose limiting lung toxicity. Albeit showing radiation-induced lung pathologies, current mouse models lack the sensitivity to do so. Using micro image-guided radiotherapy (µIGRT) techniques, we aimed to establish murine models which enable the sensitive detection of lung damage aggravation and characterized functional, radiological and histological responses. Right lungs of C57Bl/6J mice were irradiated using µIGRT with doses from 15 to 27 Gy and with 21 Gy and cisplatin as a radio-sensitizer in a second study. Mice were sacrificed for histological and pathological assessment at different time-points post-IR. Lung density was determined using the integrated micro cone-beam CT (µCBCT). Lung function was measured by double-chamber-plethysmography. µIGRT resulted in accurate deposition of the radiation dose in the right lung only as determined by ɣH2AX staining. Lung fibrosis was confirmed by pathological assessments and increased significantly at 21 Gy as determined by automated quantification of histochemical analyses. Lung function was affected in a dose-dependent manner. µCBCT-determined lung densities increased significantly over time in the irradiated lungs and showed a strong radiation dose-dependence. Importantly, the µCBCT analyses allowed the detection of additional lung damage caused by 3 Gy dose increments or by the combination with cisplatin. µCBCT after right lung µIGRT enables the sensitive detection of effects inflicted by relative small dose increments or radio-sensitizers. Our preclinical model therefore facilitates the determination of lung damage exacerbation for the safety assessment of novel RT-drug combinations.

Sections du résumé

BACKGROUND AND PURPOSE
Preclinical models are much needed to assess the effect of novel radio-sensitizers or mitigators on radiation dose limiting lung toxicity. Albeit showing radiation-induced lung pathologies, current mouse models lack the sensitivity to do so. Using micro image-guided radiotherapy (µIGRT) techniques, we aimed to establish murine models which enable the sensitive detection of lung damage aggravation and characterized functional, radiological and histological responses.
MATERIALS AND METHODS
Right lungs of C57Bl/6J mice were irradiated using µIGRT with doses from 15 to 27 Gy and with 21 Gy and cisplatin as a radio-sensitizer in a second study. Mice were sacrificed for histological and pathological assessment at different time-points post-IR. Lung density was determined using the integrated micro cone-beam CT (µCBCT). Lung function was measured by double-chamber-plethysmography.
RESULTS
µIGRT resulted in accurate deposition of the radiation dose in the right lung only as determined by ɣH2AX staining. Lung fibrosis was confirmed by pathological assessments and increased significantly at 21 Gy as determined by automated quantification of histochemical analyses. Lung function was affected in a dose-dependent manner. µCBCT-determined lung densities increased significantly over time in the irradiated lungs and showed a strong radiation dose-dependence. Importantly, the µCBCT analyses allowed the detection of additional lung damage caused by 3 Gy dose increments or by the combination with cisplatin.
CONCLUSION
µCBCT after right lung µIGRT enables the sensitive detection of effects inflicted by relative small dose increments or radio-sensitizers. Our preclinical model therefore facilitates the determination of lung damage exacerbation for the safety assessment of novel RT-drug combinations.

Identifiants

pubmed: 31146069
pii: S0167-8140(19)30406-2
doi: 10.1016/j.radonc.2019.05.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-24

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

D van Berlo (D)

Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

A Khmelinskii (A)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

A Gasparini (A)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

F J Salguero (FJ)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

B Floot (B)

Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

N de Wit (N)

Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

M van de Ven (M)

Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

J Y Song (JY)

Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

R P Coppes (RP)

Department of Radiation Oncology and Department of Biomedical Sciences of Cells & Systems, Section Molecular Cell Biology, University Medical Center Groningen, The Netherlands.

M Verheij (M)

Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

J J Sonke (JJ)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

C Vens (C)

Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: c.vens@nki.nl.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH